Hepatitis B-associated acute liver failure: Immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae

Digestion

Volumn 80, Issue 4, 2009, Pages 235-240

  Jochum, Christoph ^a   Gieseler, Robert K ^a,b   Gawlista, Isabella ^a   Fiedler, A ^a   Manka, Paul ^a   Saner, Fuat H ^a   Roggendorf, Michael ^a   Gerken, Guido ^a   Canbay, Ali ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Rodos BioTarget GmbH   (Germany)

Author keywords

Acute liver failure; Apoptosis; Cell death; Hepatitis B surface antigen; Hepatitis B virus infection; Necrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; HEPATITIS B SURFACE ANTIBODY; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CELL DEATH; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TOLERABILITY; EARLY INTERVENTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CELL; LIVER FAILURE; LIVER NECROSIS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; SEROLOGY; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CELL DEATH; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER FAILURE, ACUTE; MALE; PROSPECTIVE STUDIES; VIRUS REPLICATION; YOUNG ADULT;

EID: 70349892270     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000236009     Document Type: Article

References (27)

1. O'Grady JG: Acute liver failure. Postgrad Med J 2005; 81: 148-154.
2. Escorsell A, Mas A, De la Mata M: Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 2007; 13: 1389-1395.
3. Koskinas J, Deutsch M, Kountouras D, Kostopanagiotou G, Arkadopoulos N, Smyrniotis V, Rapti I, Manesis E, Archimandritis A: Aetiology and outcome of acute hepatic failure in Greece: experience of two academic hospital centres. Liver Int 2008; 28: 821-827.
4. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, Graziadei I, Encke J, Schmidt H, Vogel W, Schneider A, Spengler U, Gerken G, Dalekos GN, Wedemeyer H, Manns MP: Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-263.
5. Teo EK, Ostapowicz G, Hussain M, Lee WM, Fontana RJ, Lok AS: Hepatitis B infection in patients with acute liver failure in the United States. Hepatology 2001; 33: 972-976.
6. Seremba E, Sanders CM, Jain MK, Davern TJ, Rossaro L, Fontana RJ, Han S, Lee WM: Use of nucleoside analogues in HBV related acute liver failure. Hepatology 2007; 46: 95.
7. Rivero M, Crespo J, Fabrega E, Casafont F, Mayorga M, Gomez-Fleitas M, Pons-Romero F: Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat 2002; 9: 107-113.
8. Palumbo E: Entecavir for chronic hepatitis B: a review. Ther Drug Monit 2008; 30: 1-4.
9. Rutherford A, Chung RT: Acute liver failure: mechanisms of hepatocyte injury and regeneration. Semin Liver Dis 2008; 28: 167-174.
10. Bechmann LP, Marquitan G, Jochum C, Saner F, Gerken G, Canbay A: Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute-on-chronic liver failure. Liver Int 2008; 28: 713-716.
11. Rutherford AE, Hynan LS, Borges CB, Forcione DG, Blackard JT, Lin W, Gorman AR, Shaikh OS, Reuben A, Harrison E, Reddy KR, Le WM, Chung RT: Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol 2007; 5: 1477-1483.
12. Girke J, Wedemeyer H, Wiegand J, Manns MP, Tillmann HL: Acute hepatitis B: is antiviral therapy indicated? Two case reports (in German). Dtsch Med Wochenschr 2008; 133: 1178-1182.
13. Gerken G, Paterlini P, Kremsdorf D, Petit MA, Manns M, Meyer zum Buschenfelde KH, Brechot C: Clinical significance of the polymerase chain reaction (PCR) assay in chronic HBV carriers. Arch Virol Suppl 1992; 4: 97-101.
14. Gerken G, Paterlini P, Manns M, Housset C, Terre S, Dienes HP, Hess G, Gerlich WH, Berthelot P, Meyer zum Buschenfelde KH, et al: Assay of hepatitis B virus DNA by polymerase chain reaction and its relationship to pre-s- and s-encoded viral surface antigens. Hepatology 1991; 13: 158-166.
15. Frosner GG, Schomerus H, Wiedmann KH, Zachoval R, Bayerl B, Backer U, Gathof GA, Sugg U: Diagnostic significance of quantitative determination of hepatitis B surface antigen in acute and chronic hepatitis b infection. Eur J Clin Microbiol 1982; 1: 52-58.
16. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P: Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
17. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP: Population-based surveillance for acute liver failure. Am J Gastroenterol 2007; 102: 2459-2463.
18. Forman LM, Lucey MR: Predicting the prognosis of chronic liver disease: an evolution from child to meld. Mayo end-stage liver disease. Hepatology 2001; 33: 473-475.
19. Yantorno SE, Kremers WK, Ruf AE, Trentadue JJ, Podesta LG, Villamil FG: Meld is superior to King's College and Clichy's criteria to assess prognosis in fulminant hepatic failure. Liver Transpl 2007; 13: 822-828.
20. Bernal W, Cross TJ, Auzinger G, Sizer E, Heneghan MA, Bowles M, Muiesan P, Rela M, Heaton N, Wendon J, O'Grady JG: Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol 2009; 50: 306-313.
21. Volkmann X, Anstaett M, Hadem J, Stiefel P, Bahr MJ, Lehner F, Manns MP, Schulze-Osthoff K, Bantel H: Caspase activation is associated with spontaneous recovery from acute liver failure. Hepatology 2008; 47: 1624-1633.
22. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, Sharma BC, Sarin SK: A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97-101.
23. Pawlotsky JM: EASL clinical practice guidelines. J Hepatol 2009; 50: 243.
24. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R: Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108.
25. Kamar N, Milioto O, Alric L, El Kahwaji L, Cointault O, Lavayssiere L, Saune K, Izopet J, Rostaing L: Entecavir therapy for adefovirresistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-614.
26. Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ: Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008; 52: 598-605.
27. Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H: Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008; 23: 1320-1326.